Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-Current Assets (2022 - 2025)

NewAmsterdam Pharma's Non-Current Assets history spans 4 years, with the latest figure at $93.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 7653.44% year-over-year to $93.6 million; the TTM value through Dec 2025 reached $194.1 million, up 4209.44%, while the annual FY2025 figure was $93.6 million, 7653.44% up from the prior year.
  • Non-Current Assets for Q4 2025 was $93.6 million at NewAmsterdam Pharma, up from $54.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $93.6 million in Q4 2025 and bottomed at $306000.0 in Q4 2023.
  • The 4-year median for Non-Current Assets is $1.3 million (2024), against an average of $28.4 million.
  • The largest annual shift saw Non-Current Assets plummeted 99.64% in 2023 before it surged 7653.44% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $85.1 million in 2022, then tumbled by 99.64% to $306000.0 in 2023, then soared by 294.44% to $1.2 million in 2024, then soared by 7653.44% to $93.6 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Non-Current Assets are $93.6 million (Q4 2025), $54.1 million (Q3 2025), and $45.3 million (Q2 2025).